Different origins of lysophospholipid mediators between coronary and peripheral arteries in acute coronary syndrome[S]

Lysophosphatidic acids (LysoPAs) and lysophosphatidylserine (LysoPS) are emerging lipid mediators proposed to be involved in the pathogenesis of acute coronary syndrome (ACS). In this study, we attempted to elucidate how LysoPA and LysoPS become elevated in ACS using human blood samples collected simultaneously from culprit coronary arteries and peripheral arteries in ACS subjects. We found that: 1) the plasma LysoPA, LysoPS, and lysophosphatidylglycerol levels were not different, while the lysophosphatidylcholine (LysoPC), lysophosphatidylinositol, and lysophosphatidylethanolamine (LysoPE) levels were significantly lower in the culprit coronary arteries; 2) the serum autotaxin (ATX) level was lower and the serum phosphatidylserine-specific phospholipase A1 (PS-PLA1) level was higher in the culprit coronary arteries; 3) the LysoPE and ATX levels were significant explanatory factors for the mainly elevated species of LysoPA, except for 22:6 LysoPA, in the peripheral arteries, while the LysoPC and LysoPE levels, but not the ATX level, were explanatory factors in the culprit coronary arteries; and 4) 18:0 and 18:1 LysoPS were significantly correlated with PS-PLA1 only in the culprit coronary arteries. In conclusion, the origins of LysoPA and LysoPS might differ between culprit coronary arteries and peripheral arteries, and substrates for ATX, such as LysoPC and LysoPE, might be important for the generation of LysoPA in ACS.

[1]  K. Segawa,et al.  Exposure of phosphatidylserine on the cell surface , 2016, Cell Death and Differentiation.

[2]  H. Daida,et al.  Blood levels of serotonin are specifically correlated with plasma lysophosphatidylserine among the glycero-lysophospholipids , 2015, BBA clinical.

[3]  L. Becker,et al.  Phospholipid alterations in the brain and heart in a rat model of asphyxia-induced cardiac arrest and cardiopulmonary bypass resuscitation , 2015, Molecular and Cellular Biochemistry.

[4]  J. Cyster,et al.  The lysophosphatidylserine receptor GPR174 constrains regulatory T cell development and function , 2015, The Journal of experimental medicine.

[5]  M. Kurano,et al.  A New Enzyme Immunoassay for the Quantitative Determination of Classical Autotaxins (ATXα, ATXβ, and ATXγ) and Novel Autotaxins (ATXδ and ATXε) , 2015, PloS one.

[6]  M. Kurano,et al.  Lysophosphatidylserine has Bilateral Effects on Macrophages in the Pathogenesis of Atherosclerosis. , 2015, Journal of atherosclerosis and thrombosis.

[7]  H. Daida,et al.  Possible Involvement of Minor Lysophospholipids in the Increase in Plasma Lysophosphatidic Acid in Acute Coronary Syndrome , 2015, Arteriosclerosis, thrombosis, and vascular biology.

[8]  J. Aoki,et al.  Novel lysophosphoplipid receptors: their structure and function , 2014, Journal of Lipid Research.

[9]  J. Aoki,et al.  Separation and quantification of 2-acyl-1-lysophospholipids and 1-acyl-2-lysophospholipids in biological samples by LC-MS/MS , 2014, Journal of Lipid Research.

[10]  K. Sakimura,et al.  Lysophospholipid acyltransferases mediate phosphatidylcholine diversification to achieve the physical properties required in vivo. , 2014, Cell metabolism.

[11]  A. Morris,et al.  Arguing the case for the autotaxin-lysophosphatidic acid-lipid phosphate phosphatase 3-signaling nexus in the development and complications of atherosclerosis. , 2014, Arteriosclerosis, thrombosis, and vascular biology.

[12]  K. Shimada,et al.  Increased lysophosphatidic acid levels in culprit coronary arteries of patients with acute coronary syndrome. , 2013, Atherosclerosis.

[13]  Aldons J. Lusis,et al.  Identification of CAD candidate genes in GWAS loci and their expression in vascular cells[S] , 2013, Journal of Lipid Research.

[14]  Yueyue Fu,et al.  Role of erythrocytes and platelets in the hypercoagulable status in polycythemia vera through phosphatidylserine exposure and microparticle generation , 2013, Thrombosis and Haemostasis.

[15]  A. Morris,et al.  Lipid Phosphate Phosphatase 3 Negatively Regulates Smooth Muscle Cell Phenotypic Modulation to Limit Intimal Hyperplasia , 2013, Arteriosclerosis, thrombosis, and vascular biology.

[16]  H. Ren,et al.  Lipid phosphate phosphatase (LPP3) and vascular development. , 2013, Biochimica et biophysica acta.

[17]  G. Luo,et al.  Apolipoprotein A-I mimetic peptide inhibits atherosclerosis by altering plasma metabolites in hypercholesterolemia. , 2012, American journal of physiology. Endocrinology and metabolism.

[18]  K. Shimada,et al.  Increased circulating plasma lysophosphatidic acid in patients with acute coronary syndrome. , 2012, Clinica chimica acta; international journal of clinical chemistry.

[19]  N. Samadi,et al.  Regulation of lysophosphatidate signaling by autotaxin and lipid phosphate phosphatases with respect to tumor progression, angiogenesis, metastasis and chemo-resistance. , 2011, Biochimie.

[20]  N. Hayashi,et al.  A novel enzyme immunoassay for the determination of phosphatidylserine-specific phospholipase A(1) in human serum samples. , 2010, Clinica chimica acta; international journal of clinical chemistry.

[21]  J. Aoki,et al.  Emerging lysophospholipid mediators, lysophosphatidylserine, lysophosphatidylthreonine, lysophosphatidylethanolamine and lysophosphatidylglycerol. , 2009, Prostaglandins & other lipid mediators.

[22]  D. Herr,et al.  Lysophosphatidic acid in vascular development and disease , 2009, IUBMB life.

[23]  G. Mills,et al.  Autotaxin/Lysopholipase D and Lysophosphatidic Acid Regulate Murine Hemostasis and Thrombosis* , 2009, Journal of Biological Chemistry.

[24]  K. Huber,et al.  Prognostic value of apoptosis markers in advanced heart failure patients. , 2008, European heart journal.

[25]  A. Morris,et al.  Roles of lysophosphatidic acid in cardiovascular physiology and disease. , 2008, Biochimica et biophysica acta.

[26]  Y. Yatomi,et al.  Measurement of plasma lysophosphatidic acid concentration in healthy subjects: strong correlation with lysophospholipase D activity , 2008, Annals of clinical biochemistry.

[27]  S. Steinhubl,et al.  Individual Heterogeneity in Platelet Response to Lysophosphatidic Acid: Evidence for a Novel Inhibitory Pathway , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[28]  M. Nangaku,et al.  Validation of an autotaxin enzyme immunoassay in human serum samples and its application to hypoalbuminemia differentiation. , 2008, Clinica chimica acta; international journal of clinical chemistry.

[29]  King-Jen Chang,et al.  Lysophosphatidic acid regulates inflammation-related genes in human endothelial cells through LPA1 and LPA3. , 2007, Biochemical and biophysical research communications.

[30]  A. Langer,et al.  Increased Soluble Fas Plasma Levels in Subjects at High Cardiovascular Risk: Atorvastatin on Inflammatory Markers (AIM) Study, a Substudy of ACTFAST , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[31]  C. Mummery,et al.  Autotaxin, a Secreted Lysophospholipase D, Is Essential for Blood Vessel Formation during Development , 2006, Molecular and Cellular Biology.

[32]  W. Siess,et al.  Thrombogenic and atherogenic activities of lysophosphatidic acid , 2004, Journal of cellular biochemistry.

[33]  A. A. Spector,et al.  Plaque rupture, lysophosphatidic acid, and thrombosis. , 2003, Circulation.

[34]  S. Imamura,et al.  A novel colorimetric assay for the determination of lysophosphatidic acid in plasma using an enzymatic cycling method. , 2003, Clinica chimica acta; international journal of clinical chemistry.

[35]  R. Taguchi,et al.  Serum Lysophosphatidic Acid Is Produced through Diverse Phospholipase Pathways* , 2002, The Journal of Biological Chemistry.

[36]  R. Taguchi,et al.  A Novel Phosphatidic Acid-selective Phospholipase A1That Produces Lysophosphatidic Acid* , 2002, The Journal of Biological Chemistry.

[37]  H. Arai,et al.  Structure and function of phosphatidylserine-specific phospholipase A1. , 2002, Biochimica et biophysica acta.

[38]  W. Siess.  Athero- and thrombogenic actions of lysophosphatidic acid and sphingosine-1-phosphate. , 2002, Biochimica et biophysica acta.

[39]  A. Morris,et al.  Roles for lipid phosphate phosphatases in regulation of cellular signaling. , 2002, Biochimica et biophysica acta.

[40]  G. Tigyi.  Physiological responses to lysophosphatidic acid and related glycero-phospholipids. , 2001, Prostaglandins & other lipid mediators.

[41]  M. Setaka,et al.  Simultaneous separation of lysophospholipids from the total lipid fraction of crude biological samples using two-dimensional thin-layer chromatography. , 2000, Journal of lipid research.

[42]  J. Berliner,et al.  Lysophosphatidic acid as a regulator of endothelial/leukocyte interaction. , 1999, Laboratory investigation; a journal of technical methods and pathology.

[43]  Hiroyuki Arai,et al.  Molecular Cloning and Characterization of a Novel Human G-protein-coupled Receptor, EDG7, for Lysophosphatidic Acid* , 1999, The Journal of Biological Chemistry.

[44]  M. Aepfelbacher,et al.  Lysophosphatidic acid mediates the rapid activation of platelets and endothelial cells by mildly oxidized low density lipoprotein and accumulates in human atherosclerotic lesions. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[45]  P. Fox,et al.  Role of lysophosphatidylcholine in the inhibition of endothelial cell motility by oxidized low density lipoprotein. , 1996, The Journal of clinical investigation.

[46]  A. Bruni,et al.  Role of a serum phospholipase A1 in the phosphatidylserine‐induced T cell inhibition , 1993, FEBS letters.

[47]  D. Vance,et al.  Comparison of albumin-mediated release of lysophosphatidylcholine and lysophosphatidylethanolamine from cultured rat hepatocytes. , 1989, The Biochemical journal.

[48]  S. Robins,et al.  Origin of plasma lysophosphatidylcholine: evidence for direct hepatic secretion in the rat. , 1985, The Journal of laboratory and clinical medicine.

[49]  J. Glomset,et al.  The plasma lecithins:cholesterol acyltransferase reaction. , 1968, Journal of lipid research.